FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine and concerns a pharmaceutical composition and a kit for treating antigen G250 expressing cancer. The pharmaceutical composition contains an antigen G250 specific antibody and/or a fragment thereof. The composition is used as an adjuvant therapy in the patient with a primary tumour, wherein the patient has been exposed to the primary tumour exsection, and a lymphadenectomy if necessary, and wherein the patient has been diagnosed with a non-metastasising disease. What is also presented is the kit containing the antigen G250 specific antibody and/or the fragment thereof.
EFFECT: group of inventions provides reducing the tumour recurrence in the patients.
16 cl, 4 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMPROVED SUPPORTING THERAPY OF TUMOURS EXPRESSING G250 | 2005 |
|
RU2371198C2 |
| TREATMENT OF MALIGNANT NEOPLASMS BASED ON CAIX STRATIFICATION | 2014 |
|
RU2663694C2 |
| SELECTIVE DETECTION OF BONE METASTASES IN CLEAR CELL RENAL CELL ADENOCARCINOMA | 2010 |
|
RU2536290C2 |
| METHOD FOR PREDICTION OF ONCOLOGICAL SURVIVAL RATE IN PATIENTS WITH NONMETASTATIC RENAL CELL CARCINOMA AFTER MALIGNANT NEPHRECTOMY OR PARTIAL NEPHRECTOMY | 2010 |
|
RU2438127C1 |
| METHOD FOR EARLY DIAGNOSIS OF RENAL CELL CARCINOMA BY THE PRESENCE OF ANTIBODIES TO THE VISUAL ARRESTIN | 2018 |
|
RU2707884C1 |
| METHOD FOR EARLY DIAGNOSIS OF RENAL CELL CARCINOMA BY OBSERVING PRESENCE OF VISUAL ARRESTIN IN BLOOD SERUM | 2020 |
|
RU2741245C1 |
| METHOD OF DIAGNOSING RENAL CELL CARCINOMA BY PRESENCE OF ARRESTIN AND RECOVERIN VISUAL PROTEINS IN URINE | 2022 |
|
RU2805811C1 |
| PD-1/PD-L1 INHIBITORS FOR TREATING CANCER | 2016 |
|
RU2742312C1 |
| PD-1/PD-L1 INHIBITORS FOR TREATING CANCER | 2016 |
|
RU2714233C2 |
| METHOD FOR BLADDER CANCER COURSE PREDICTION | 2017 |
|
RU2641170C1 |
